| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 35.91 | 0.03 (+0.08%) | 11.05 - 37.80 | 417.2 thousand (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 35.81 |
|---|---|
| Previous Close | 35.88 |
| Day's Range | 35.81 - 37.80 |
| Market Cap | 1.2B |
| Avg Volume (10 Day) | 248.8K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -22.38 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Art Pappas Elected to NVCA Board of Directors
PR Newswire - Wednesday 05/15/2013 11:23 AM ET
| TSRO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| Sarepta Therapeutics Inc | 36.91 | +3.94% |
| PDL BioPharma Inc | 8.22 | +0.49% |
| Infinity Pharmaceuticals Inc | 24.91 | +2.43% |
| Lexicon Pharmaceuticals Inc | 2.21 | +1.38% |
Data is delayed by at least 15 min.